Literature DB >> 10770722

Financial impact of a home intravenous antibiotic program on a medicare managed care program.

J R Dalovisio1, J Juneau, K Baumgarten, J Kateiva.   

Abstract

This study quantitates cost savings achieved by a home intravenous antibiotic (HIVA) program in a Medicare managed health care program. In 1998, 66 treatment courses of HIVA therapy were administered for a total of 1542 patient-days of therapy. The calculated cost of HIVA therapy included the actual costs of drugs, supplies, nursing and therapists' salaries, and laboratory studies. Savings were calculated based on the average daily direct variable cost (DDVC) for hospital acute unit or skilled nursing facility (SNF) care associated with the patient's discharge diagnosis-related-group. The number of days on HIVA therapy was assumed to equal the number of days in the hospital acute unit or hospital-based SNF. The average cost per day of HIVA therapy was $122, whereas average DDVC of hospital acute unit care was $798, and the average DDVC of SNF care was $541. In 1 year, the HIVA program saved our health care system $646,000-$834,000, which demonstrates that HIVA programs are powerful tools to reduce costs in Medicare managed health care programs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10770722     DOI: 10.1086/313755

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  12 in total

1.  What Medicare Is Missing.

Authors:  Sara Keller; Peter Pronovost; Sara Cosgrove
Journal:  Clin Infect Dis       Date:  2015-09-03       Impact factor: 9.079

2.  Hospital costs for patients with lower extremity cellulitis: a retrospective population-based study.

Authors:  Douglas Challener; Jasmine Marcelin; Sue Visscher; Larry Baddour
Journal:  Hosp Pract (1995)       Date:  2017-09-27

3.  Risk Factors Associated With Nephrotoxicity During Outpatient Intravenous Vancomycin Administration.

Authors:  Karen M Krueger; Lisa LaCloche; Amy Buros Stein; Ryan Kates; Milena Murray; Michael P Angarone
Journal:  J Pharm Technol       Date:  2021-11-18

4.  Comparison of outcomes and operative course between septic and aseptic nonunion in long bones.

Authors:  Lucas Haase; Tyler Moon; Andrew Burcke; Jacob Speybroeck; Robert Wetzel; John Sontich; George Ochenjele; Joshua Napora
Journal:  Eur J Orthop Surg Traumatol       Date:  2022-08-29

5.  Factors associated with complications and mortality in adult patients hospitalized for infectious cellulitis.

Authors:  J Carratalà; B Rosón; N Fernández-Sabé; E Shaw; O del Rio; A Rivera; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-03-05       Impact factor: 3.267

6.  Learning from the patient: Human factors engineering in outpatient parenteral antimicrobial therapy.

Authors:  Sara C Keller; Ayse P Gurses; Alicia I Arbaje; Sara E Cosgrove
Journal:  Am J Infect Control       Date:  2016-03-02       Impact factor: 2.918

7.  Home intravenous antibiotics in a tertiary care hospital in Saudi Arabia.

Authors:  Salim Baharoon; Hind Almodaimeg; Haifa Al Watban; Hamdan Al Jahdali; Thamer Alenazi; Abdullah Al Sayyari; Abdulaziz Al Dawood; Mohammed Al-Sultan; Eiman Al Safi
Journal:  Ann Saudi Med       Date:  2011 Sep-Oct       Impact factor: 1.526

Review 8.  Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: CIVAS systematic review.

Authors:  E D Mitchell; C Czoski Murray; D Meads; J Minton; J Wright; M Twiddy
Journal:  BMJ Open       Date:  2017-04-20       Impact factor: 2.692

9.  Out Of Hospital And In Hospital Management Of Cellulitis Requiring Intravenous Therapy.

Authors:  Bin S Ong; Vincent Jiu Jong Ngian; Clarence Yeong; Caitlin Keighley
Journal:  Int J Gen Med       Date:  2019-11-29

10.  Bundle in the Bronx: Impact of a Transition-of-Care Outpatient Parenteral Antibiotic Therapy Bundle on All-Cause 30-Day Hospital Readmissions.

Authors:  Theresa Madaline; Priya Nori; Wenzhu Mowrey; Elisabeth Zukowski; Shruti Gohil; Uzma Sarwar; Gregory Weston; Riganni Urrely; Matthew Palombelli; Vinnie Frank Pierino; Vanessa Parsons; Amy Ehrlich; Belinda Ostrowsky; Marilou Corpuz; Liise-Anne Pirofski
Journal:  Open Forum Infect Dis       Date:  2017-06-29       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.